Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Several aggregation-prone proteins such as the amyloid-beta (Aβ) peptides, tau proteins, and α-synuclein protein are involved in secondary pathogenic cascades initiated by a TBI and are also major building blocks of the hallmark pathological lesions in chronic human neurodegenerative diseases with dementia.
|
29933008 |
2019 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Erythrocytes as Biomarkers for Dementia: Analysis of Protein Content and Alpha-Synuclein.
|
31424413 |
2019 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively analysed myocardial MIBG images acquired with a dual-head gamma camera and low-energy high-resolution collimator (LEHR) in 194 patients with suspected synucleinopathy or atypical parkinsonism, including 34 with genetic Parkinson's disease (PD; 4 PARK1, 8 PARK2 and 22 PARK8), 85 with idiopathic PD (iPD), 6 with idiopathic REM sleep behaviour disorder (iRBD), 17 with dementia with LB (DLB), 40 with multiple system atrophy (MSA) and 12 with progressive supranuclear palsy (PSP), and in 45 healthy controls.
|
30324423 |
2019 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PD patients carrying the protective GG genotype at SNCA rs11931074 may be at significantly higher risk of dementia than patients with other genotypes.
|
31102707 |
2019 |
Dementia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
New analytical methods for precise quantification of cerebrospinal fluid (CSF) levels of both tau and α-synuclein are required to differentiate between dementias or monitor therapeutic responses.
|
31553333 |
2019 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
The α-synuclein is a major component of amyloid fibrils found in Lewy bodies, the characteristic intracellular proteinaceous deposits which are pathological hallmarks of neurodegenerative diseases such as Parkinson's disease (PD) and dementia.
|
30635607 |
2019 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Chronic alpha-synuclein (<i>SNCA</i>) overexpression is a relatively homogenous and well-defined cause of parkinsonism and dementia.
|
30619023 |
2018 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
|
30083953 |
2018 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Prion-Like Seeding of Misfolded α-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC.
|
28550528 |
2018 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We screened for the p. A53T SNCA mutation a total of 347 cases of Greek origin with parkinsonism and/or dementia, collected over 15 years at the Neurogenetics Unit, Eginition Hospital, University of Athens.
|
29233723 |
2018 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
In the replication cohort (n = 40), the total tau/α-synuclein and total tau/amyloid ß1-42+α-synuclein ratios were associated with progression to dementia over a 41-month follow-up.
|
30423201 |
2018 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Current platelet protein biomarkers that have been investigated for their clinical utility in the diagnosis of dementia, in particular Alzheimer's disease, include amyloid-β protein precursor (AβPP), the AβPP secretases (BACE1 and ADAM10), α-synuclein, tau protein, serotonin, cholesterol, phospholipases, clusterin, IgG, surface receptors, MAO-B, and coated platelets.
|
29843245 |
2018 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the unraveled tau-mediated signaling cascade may contribute to the pathogenesis of dementia in A53T α-synuclein-linked familial PD cases, as well as some subgroups of PD cases with extensive tau pathology.<b>SIGNIFICANCE STATEMENT</b> Here, we report mutation-specific postsynaptic deficits that are caused by A53T mutant α-synuclein, which is linked to familial Parkinson's disease (PD).
|
30249789 |
2018 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
This set of data indicates that α-synuclein misfolding is the essential mechanism causing the lesions of Parkinson disease and dementia with Lewy body.
|
29869713 |
2018 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Multivariate regression showed independent negative associations of cerebral tau neurofibrillary tangles score with the interval between onset of motor and dementia symptoms (β -4·0, 95% CI -5·5 to -2·6; p<0·0001; R<sup>2</sup> 0·22, p<0·0001) and with survival (-2·0, -3·2 to -0·8; 0·003; 0·15, <0·0001) in models that included age at death, sex, cerebral neuritic plaque scores, cerebral α-synuclein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genotype as covariates.
|
27979356 |
2017 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Lewy body dementia is the second most common neurodegenerative dementia and is pathologically characterized by α-synuclein positive cytoplasmic inclusions, with varying amounts of amyloid-β (Aβ) and hyperphosphorylated tau (tau) aggregates in addition to synaptic loss.
|
28269775 |
2017 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Perirhinal accumulation of neuronal alpha-synuclein in a multiple system atrophy patient with dementia.
|
28419566 |
2017 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Generated antibodies recognize misfolded hα-Syn produced by neuroblastoma cells, hα-Syn in the brain tissues of transgenic mouse strains and in the brain tissues of dementia with Lewy body cases.
|
28870518 |
2017 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
A neurodegenerative disorder displaying an altered α-synuclein (αS) in the brain tissue is called α-synucleinopathy (αS-pathy) and incorporates clinical entities such as Parkinson disease (PD), PD with dementia, dementia with Lewy bodies, and multiple-system atrophy.
|
28987181 |
2017 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
Abnormal accumulation of alpha-synuclein (αsyn) is a pathological hallmark of Lewy body related disorders such as Parkinson's disease and Dementia with Lewy body disease.
|
28645308 |
2017 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Synucleinopathies are a spectrum of neurodegenerative diseases characterized by the intracellular deposition of the protein α-synuclein leading to multiple outcomes, including dementia and Parkinsonism.
|
28910367 |
2017 |
Dementia
|
0.200 |
Biomarker
|
disease |
BEFREE |
We assessed aging-related neurodegenerative lesions, i.e., misfolded proteins, associated with dementia such as hyperphosphorylated τ (HPτ), Aβ, α-synuclein (αS), and phosphorylated transactive DNA binding protein 43 (pTDP43) seen in the brain and IAPP seen in the pancreas in subjects with and without DM applying immunohistochemical techniques.
|
28582864 |
2017 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Disorders with progressive accumulation of α-synuclein (α-syn) are a common cause of dementia and parkinsonism in the aging population.
|
28476636 |
2017 |
Dementia
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Support for this thesis is based on these observations: (1) heat shock induces improvements in synapse integrity and memory consolidation; (2) synaptic depolarization activates HSF1; (3) activation of HSF1 alone (independent of the canonical heat shock response) augments formation of essential synaptic elements-neuroligands, vesicle transport, synaptic scaffolding proteins, lipid rafts, synaptic spines, and axodendritic synapses; (4) HSF1 coalesces and activates memory receptors in the post-synaptic dendritic spine; (5) huntingtin or α-synuclein accumulation lowers HSF1 while HSF1 lowers huntingtin and α-synuclein aggregation-a potential vicious cycle; and (6) HSF1 agonists (including physical activity) can improve cognitive function in dementia models.
|
27283588 |
2016 |
Dementia
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Alpha-synuclein (SNCA) was first implicated in the pathogenesis of the disease when point mutations and locus multiplications were identified in familial parkinsonism with dementia.
|
27091628 |
2016 |